UNSPSC 51263403: Spirendolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C21H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96789094BR, chemically known as spiro(cyclohexane-1,2-(2h)inden)-1(3h)-one, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-, (+-)- but generally known as spirendolol, which bears US NIH Compound Identifier 68857. European Medicines Agency schedules Spirendolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10623MIG.

UNSPSC 51263403 Spirendolol is a Commodity code that does not reflect the work actually being solicited under it in recent state and local procurement activity. The two most recent opportunities tagged to this code involve naloxone procurement and direct-to-manufacturer prescription program design—neither of which is spirendolol or closely related pharmaceutical products. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to its Community Health Building; the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on implementing a direct-to-manufacturer prescription program for state pharmacy benefit programs. The code shows little relevant recent activity and appears to be a tagging error or artifact within the state and local procurement system rather than an active commodity category for spirendolol itself.

The geographic spread of recent activity is limited to Florida and Texas, with no additional states represented in the posted opportunities. Beyond the mismatch between the code's nominal scope and actual solicitations, activity under this code does not support a meaningful business development strategy for firms pursuing spirendolol contracts with state and local buyers.